Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


11.11.2019

1 AJR Am J Roentgenol
1 Am J Clin Oncol
2 Ann Surg Oncol
6 Ann Thorac Surg
1 BMC Cancer
1 Cancer
1 Cancer Epidemiol Biomarkers Prev
2 Cancer Lett
1 Cancer Sci
2 Clin Cancer Res
1 Clin Lung Cancer
2 Clin Nucl Med
1 Int J Cancer
1 J Cancer Res Clin Oncol
1 J Clin Invest
1 J Clin Oncol
15 J Thorac Oncol
4 Lung Cancer
1 Lung Cancer (Auckl)
1 Semin Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. OHNO Y, Yui M, Aoyagi K, Kishida Y, et al
    Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
    AJR Am J Roentgenol. 2018 Dec 4:1-9. doi: 10.2214/AJR.18.20111.
    PubMed     Text format     Abstract available


    Am J Clin Oncol

  2. D'ANDREA MA, Reddy GK
    Extracranial Abscopal Responses in Advanced Lung Cancer Induced by Brain Radiation.
    Am J Clin Oncol. 2019 Oct 30. doi: 10.1097/COC.0000000000000623.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  3. KARUSH JM
    Are Lobe-Specific Mediastinal Lymph Node Dissections Reasonable for Peripheral Stage Ia Non-small Cell Lung Cancer?
    Ann Surg Oncol. 2019 Nov 6. pii: 10.1245/s10434-019-08069.
    PubMed     Text format    

  4. NAKAZAWA N, Yokobori T, Turtoi A, Shirabe K, et al
    ASO Author Reflections: High Stromal TGFBI is a Useful Predictive Marker for Nivolumab in Non-small Cell Lung Cancer.
    Ann Surg Oncol. 2019 Nov 6. pii: 10.1245/s10434-019-08057.
    PubMed     Text format    


    Ann Thorac Surg

  5. GJERAA K, Dieckmann P, Spanager L, Petersen RH, et al
    Exploring Shared Mental Models of Surgical Teams in Video-Assisted Thoracoscopic Surgery Lobectomy.
    Ann Thorac Surg. 2019;107:954-961.
    PubMed     Text format     Abstract available

  6. JEAN RA, Chiu AS, Hoag JR, Blasberg JD, et al
    Identifying Drivers of Multiple Readmissions After Pulmonary Lobectomy.
    Ann Thorac Surg. 2019;107:947-953.
    PubMed     Text format     Abstract available

  7. HARLING L, Kolokotroni SM, Nair A, Smelt J, et al
    Differential Survival Characteristics of Sarcomatoid Subtype in Biphasic Pleural Mesothelioma.
    Ann Thorac Surg. 2019;107:929-935.
    PubMed     Text format     Abstract available

  8. HANDY JR, Bremner RM, Crocenzi TS, Detterbeck FC, et al
    Expert Consensus Document on Pulmonary Metastasectomy.
    Ann Thorac Surg. 2019;107:631-649.
    PubMed     Text format    

  9. VAN HAREN RM, Correa AM, Sepesi B, Rice DC, et al
    Ground Glass Lesions on Imaging: Evaluation of Reported Incidence Using Natural Language Processing.
    Ann Thorac Surg. 2018 Oct 26. pii: S0003-4975(18)31531.
    PubMed     Text format     Abstract available

  10. BRODERICK SR, Grau-Sepulveda M, Kosinski AS, Kurlansky PA, et al
    The Society of Thoracic Surgeons Composite Score Rating for Pulmonary Resection for Lung Cancer.
    Ann Thorac Surg. 2019 Nov 2. pii: S0003-4975(19)31604.
    PubMed     Text format     Abstract available


    BMC Cancer

  11. ZHANG JT, Liu SY, Yan HH, Wu YL, et al
    Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study.
    BMC Cancer. 2019;19:1051.
    PubMed     Text format     Abstract available


    Cancer

  12. BODOR JN, Boumber Y, Borghaei H
    Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).
    Cancer. 2019 Nov 6. doi: 10.1002/cncr.32468.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  13. THOMAS CE, Wang R, Adams-Haduch J, Murphy SE, et al
    Urinary cotinine is as good a biomarker as serum cotinine for cigarette smoking exposure and lung cancer risk prediction.
    Cancer Epidemiol Biomarkers Prev. 2019 Nov 4. pii: 1055-9965.EPI-19-0653.
    PubMed     Text format     Abstract available


    Cancer Lett

  14. GUPTA P, Gupta N, Fofaria NM, Ranjan A, et al
    HER2-mediated GLI2 stabilization promotes anoikis resistance and metastasis of breast cancer cells.
    Cancer Lett. 2018;442:68-81.
    PubMed     Text format     Abstract available

  15. CAPPELLI HC, Kanugula AK, Adapala RK, Amin V, et al
    Mechanosensitive TRPV4 channels stabilize VE-cadherin junctions to regulate tumor vascular integrity and metastasis.
    Cancer Lett. 2019;442:15-20.
    PubMed     Text format     Abstract available


    Cancer Sci

  16. KAMATA T, Yoshida S, Takami M, Ihara F, et al
    Immunological Features of a Lung Cancer Patient Achieving an Objective Response with Anti-PD-1 Blockade Therapy.
    Cancer Sci. 2019 Nov 2. doi: 10.1111/cas.14222.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  17. SHI R, Radulovich N, Ng C, Liu N, et al
    Organoid cultures as preclinical models of non-small cell lung cancer.
    Clin Cancer Res. 2019 Nov 6. pii: 1078-0432.CCR-19-1376.
    PubMed     Text format     Abstract available

  18. KNORR DA, Ravetch JV
    Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism.
    Clin Cancer Res. 2019;25:904-906.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  19. KNEUERTZ PJ, D'Souza DM, Richardson M, Abdel-Rasoul M, et al
    Long-Term Oncologic Outcomes After Robotic Lobectomy for Early-stage Non-Small-cell Lung Cancer Versus Video-assisted Thoracoscopic and Open Thoracotomy Approach.
    Clin Lung Cancer. 2019 Oct 13. pii: S1525-7304(19)30269.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  20. HYUN SH, Ahn MS, Koh YW, Lee SJ, et al
    A Machine-Learning Approach Using PET-Based Radiomics to Predict the Histological Subtypes of Lung Cancer.
    Clin Nucl Med. 2019;44:956-960.
    PubMed     Text format     Abstract available

  21. HYUN SH, Ahn MS, Koh YW, Lee SJ, et al
    A Machine-Learning Approach Using PET-Based Radiomics to Predict the Histological Subtypes of Lung Cancer.
    Clin Nucl Med. 2019 Oct 23. doi: 10.1097/RLU.0000000000002810.
    PubMed     Text format     Abstract available


    Int J Cancer

  22. BOSSE Y, Li Z, Xia J, Manem V, et al
    Transcriptome-wide association study reveals candidate causal genes for lung cancer.
    Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32771.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  23. CHEN D, Xu J, Zhao Y, Chu T, et al
    Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
    J Cancer Res Clin Oncol. 2019 Nov 6. pii: 10.1007/s00432-019-03064.
    PubMed     Text format     Abstract available


    J Clin Invest

  24. CHEN M, Zhang J, Berger AH, Diolombi MS, et al
    Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis.
    J Clin Invest. 2019;129:215-222.
    PubMed     Text format     Abstract available


    J Clin Oncol

  25. HOSOMI Y, Morita S, Sugawara S, Kato T, et al
    Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
    J Clin Oncol. 2019 Nov 4:JCO1901488. doi: 10.1200/JCO.19.01488.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  26. DAVID EA, Atay SM, McFadden PM, Kim AW, et al
    Sublobar or Suboptimal: Does Tumor Spread through Air Spaces Signify the End of Sublobar Resections for T1N0 Adenocarcinomas?
    J Thorac Oncol. 2019;14:11-12.
    PubMed     Text format    

  27. GOLDMAN JW, Garon EB
    Nivolumab in Previously Treated SCLC: Encouraging, but Still Awaiting the Complete Story.
    J Thorac Oncol. 2019;14:160-162.
    PubMed     Text format    

  28. CARBONE M, Yang H, Gaudino G
    Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?
    J Thorac Oncol. 2019;14:157-159.
    PubMed     Text format    

  29. ABADA PB
    Tracheoesophageal Fistula in a Patient With Advanced NSCLC Who Received Chemoradiotherapy and Ramucirumab.
    J Thorac Oncol. 2019;14:e19.
    PubMed     Text format    

  30. DRESLER C, Warren GW, Arenberg D, Yang P, et al
    Indeed, Nuance Matters.
    J Thorac Oncol. 2019;14:e16-e17.
    PubMed     Text format    

  31. STIEFEL F, Bourquin C
    Nuance Matters.
    J Thorac Oncol. 2019;14:e15.
    PubMed     Text format    

  32. MCCOACH CE
    A Cautionary Analysis of Immunotherapy Prior to Targeted Therapy.
    J Thorac Oncol. 2019;14:8-10.
    PubMed     Text format    

  33. TSOU TC, Gowen K, Ali SM, Miller VA, et al
    Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion.
    J Thorac Oncol. 2019;14:e29-e30.
    PubMed     Text format    

  34. LE T, Minna JD, Gerber DE
    Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?
    J Thorac Oncol. 2019;14:332-335.
    PubMed     Text format    

  35. MACKINTOSH JA, Marshall HM, Fong KM
    A Targeted Approach to the Complications of Targeted Therapy.
    J Thorac Oncol. 2019;14:577-579.
    PubMed     Text format    

  36. WANG Z, Wu YL
    Re-emerging C797S In Trans and Rechallenge of Osimertinib With Erlotinib.
    J Thorac Oncol. 2019;14:e81-e82.
    PubMed     Text format    

  37. CHRISTODOULOU M, Faivre-Finn C
    Author's Reply to the: Letter to the Editor.
    J Thorac Oncol. 2019;14:e63-e64.
    PubMed     Text format    

  38. MOLNAR TF, Szipocs A, Szalai Z
    Neoadjuvant Crizotinib for ALK Re-arranged NSCLC?
    J Thorac Oncol. 2019;14:574-576.
    PubMed     Text format    

  39. BUCKNELL NW, Ball D
    PCI in Small Cell-Review the Cohorts.
    J Thorac Oncol. 2019;14:e59-e60.
    PubMed     Text format    

  40. RIHAWI K, Giannarelli D, Galetta D, Delmonte A, et al
    BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience.
    J Thorac Oncol. 2019;14:e57-e59.
    PubMed     Text format    


    Lung Cancer

  41. GHIMIRE B, Maroni R, Vulkan D, Shah Z, et al
    Erratum to "Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme" [Lung Cancer 134 (August) (2019) 66-71].
    Lung Cancer. 2019 Nov 2. pii: S0169-5002(19)30677.
    PubMed     Text format    

  42. EICHHORN F, Klotz LV, Muley T, Kobinger S, et al
    Prognostic relevance of regional lymph-node distribution in patients with N1-positive non-small cell lung cancer: A retrospective single-center analysis.
    Lung Cancer. 2019;138:95-101.
    PubMed     Text format     Abstract available

  43. BAR J, Ofek E, Barshack I, Gottfried T, et al
    Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer.
    Lung Cancer. 2019;138:109-115.
    PubMed     Text format     Abstract available

  44. THOMPSON JC, Hwang WT, Davis C, Deshpande C, et al
    Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
    Lung Cancer. 2019;139:1-8.
    PubMed     Text format     Abstract available


    Lung Cancer (Auckl)

  45. TRIPHURIDET N, Henschke C
    Landscape on CT screening for lung cancer in Asia.
    Lung Cancer (Auckl). 2019;10:107-124.
    PubMed     Text format     Abstract available


    Semin Oncol

  46. KLEIN M, Scaria G, Ganti AK
    Utilization of the Veterans Affairs Central Cancer Registry to evaluate lung cancer outcomes.
    Semin Oncol. 2019 Oct 24. pii: S0093-7754(19)30063.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: